정규장
Log in Sign up
SPRC
SPRC
SciSparc Ltd
7월 28일 12:48 PM ET (한국 7/29 01:48)
$5.01
-0.32 ▼ -6.00%

사이스파크(SPRC) is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.

시황 · 실적발표 · 매수매도 신호, 가장 먼저 받아보세요 🔔 구독
시가총액
$3M
스몰캡
P/E
-
배당수익률
없음
52주 위치
3%
저점 +68% · 고점 -94%
애널리스트
-
D
Fundamental health
vs. Biotechnology 초소형주· based on 3 axes
수익성
산출 불가 (적자)
성장
Top 60%
밸류에이션
Top 87%
재무 안정
Top 48%
Index -P/E -EPS (ttm) -231.49Insider Own 1.85%Shs Outstand 0.6MPerf Week 6.6%
Market Cap 0.00BForward P/E -EPS next Y -Insider Trans -4.17%Shs Float 0.6MPerf Month -18.14%
Enterprise Value -0.00BPEG -EPS next Q -Inst Own 0.55%Short Float 1.79%Perf Quarter -25.11%
Income -0.01BP/S 3.34EPS this Y -Inst Trans -3.89%Short Ratio 0.01Perf Half Y -44.88%
Sales 0.00BP/B 0.05EPS next 5Y -ROA -135.56%Short Interest 0.01MPerf YTD -59.07%
Book/sh 104.4P/C 0.62EPS past 3/5Y 31.81% -13.87%ROE -196.55%52W High -93.75% ($80.10)Perf Year -92.33%
Cash/sh 8.03P/FCF -Sales past 3/5Y -14.03% -ROIC -287.31%52W Low 68.12% ($2.98)Perf 3Y -99.8%
Dividend Est. -EV/EBITDA -EPS Y/Y TTM 37.59%Gross Margin 46.38%Volatility(W/M) 14.02% 12.58%Perf 5Y -
Dividend TTM -EV/Sales -0.53Sales Y/Y TTM -34.46%Oper. Margin -1022.08%ATR (14) 0.77Perf 10Y -
Dividend Ex-Date -Quick Ratio 2.38EPS Q/Q -Profit Margin -1422.78%RSI (14) 44.72Recom -
Dividend Gr. 3/5Y -Current Ratio 2.41Sales Q/Q -SMA20 -0.63% ($5.04)Beta 2.47Target Price -
Payout -Debt/Eq 0.09Earnings -SMA50 -22.4% ($6.46)Rel Volume 0.11Prev Close $5.33
Employees 3LT Debt/Eq 0EPS/Sales Surpr. -SMA200 -56.39% ($11.49)Avg Volume(3M) 0.78MPrice $5.01
IPO 2021/8/30Option/Short No/YesTrades 808Volume 84,029Change -6%
Quarterly earnings trend Quarterly earnings data is not yet available — foreign-listed companies (ADRs) only file annual reports with the U.S., and recently listed companies may not have filed their first quarterly report.

📊 SciSparc Ltd (SPRC) Investment Analysis

What kind of company is SciSparc Ltd?

사이스파크(SPRC)
Healthcare · Biotechnology
Small-Cap — Low Volume, High Volatility

A clinical-stage pharmaceutical company developing therapeutics for neurological and psychiatric disorders using complex formulations based on cannabinoids and palmitoylethanolamide (PEA). Its lead candidate, SCI-110, targets Tourette's syndrome, sleep apnea, and Alzheimer's disease, among other conditions. This Israeli micro-cap company operates its clinical assets through its subsidiary, Neurotera Labs.

Learn more about SciSparc Ltd →
Market Cap
$0.0B
Approx. KRW 0.0 trillion
⚖️ 0% of Samsung Electronics
Market Cap Rank5774
Employees3people
IPO2021/08/30
Current Price$5.01 ≈ 6,864원
NASD · Israel

Key Events

예정된 이벤트가 없습니다

SPRC의 다음 실적 발표일이나 배당 일정이 아직 수집되지 않았습니다.

  • 실적 발표는 보통 분기마다 있습니다
  • 배당주는 연 1~4회 배당락일이 있습니다
전체 경제/실적 캘린더 보기 →

Is it profitable?

Financially sound but profitability is low
Losses or thin margins — early-stage growth or weakening competitiveness
Profitability — How efficiently it makes money
Operating Margin
Profit kept from selling products and services (higher is better)
-1022.1%
✓ 적자
💡 적자 상태 — 수익을 내지 못하고 있습니다
Net Margin
Share of revenue left after taxes and interest are paid
-1422.8%
✓ 적자
💡 적자 상태 — 수익을 내지 못하고 있습니다
Gross Margin
Profit after subtracting raw-material costs only (signals product competitiveness)
46.4%
✓ 평균
My positionMid-range
Low range Average High range
Biotechnology 초소형주 Median 53.4% · Bottom 47%
💡 제조업 30%, IT/소프트웨어 50% 이상이면 우수 (업종별 편차 큼)
ROE
Annual return earned on shareholders' equity (15%+ is strong)
-196.6%
✓ 적자
💡 적자 상태 — 수익을 내지 못하고 있습니다
ROA
Annual earnings relative to total company assets
-135.6%
✓ 적자
💡 적자 상태 — 수익을 내지 못하고 있습니다
ROIC
Return generated per dollar invested in the business
-287.3%
✓ 적자
💡 적자 상태 — 수익을 내지 못하고 있습니다
Financial health — Debt & liquidity burden
Debt-to-Equity (D/E)
Debt relative to equity (lower is healthier)
0.09
✓ Healthy debt
My positionMid-range
Low range Average High range
Biotechnology Median 0.05
💡 일반적으로 1.0 이하면 건전, 1.5까지는 무난 (금융·유틸·REIT는 구조적으로 높음)
Current Ratio
Liquid assets available to cover liabilities due within a year
2.41
✓ 양호
My positionMid-range
Low range Average High range
Biotechnology Median 5.75
💡 1.5~3.0 적정, 1.0 미만이면 단기 유동성 주의
Quick Ratio
Liquid assets excluding inventory, available for immediate use
2.38
✓ 양호
My positionMid-range
Low range Average High range
Biotechnology Median 5.47
💡 1.0 이상이면 안전, 0.5 미만이면 주의
* Ratings reflect relative position vs. peer-group distribution (same sector & size) plus absolute guards (loss & risk thresholds).

What's the outlook?

Outlook data is insufficient

Analyst estimates and price targets have not been collected.

Did earnings meet expectations?

Insufficient historical earnings data

No analyzable past earnings releases have been collected yet.

Is it growing?

Average Growth
Mid-range within the industry
📊 How much has it grown? (actual results)
Past 3-Year EPS
Actual average annual EPS growth over the past 3 years
+31.8%
양호
My positionMid-range
Low range Average High range
미분류 초소형주 Median 25.4% · Top 44%
Past 5-Year EPS
Actual average annual EPS growth over the past 5 years
-13.9%
부진
My positionBottom 25%
Low range Average High range
미분류 초소형주 Median 14.6% · Bottom 24%
* Forecast values are analyst consensus estimates. Ratings are determined by relative position vs. peer group of the same growth style and size.

Has the stock risen over the long term?

Underperformed the market by 108%p over the past year
SPRC -92.3% · S&P 500 +16.0%
Excess return vs. market (price-based, ex-dividends)
1-year basis
vs S&P 500
-108.3%p
Significantly behind the market
vs Health Care (XLV)
-112.0%p
Significantly behind the sector average
Rank among peers
1-year return Lowest among peers Based on 315 peers
Current position within 52-week range
Low (-68.1%p) High (-93.8%p)
Current price is 68.1% above the 52-week low and 93.8% below the 52-week high
Recent risk (last 120 trading days)
Max drawdown
-63.0%
Annualized volatility
395.5%

Technical Indicators

Bollinger Bands · MACD · RSI · Stochastics · Ichimoku 5-line · recent 136-day series

Price · Bollinger Bands · Ichimoku Cloud

  • close
  • BB Upper
  • BB Mid
  • BB Lower
  • Tenkan
  • Kijun
  • Cloud (SpanA/B)

Bollinger Bands are upper and lower channels showing the closing price range (20 days · 2σ). Touching the upper band = overheated; touching the lower band = oversold. Ichimoku Cloud shows trend direction and strength through colored areas. Prices above the cloud indicate an uptrend; prices below indicate a downtrend. About Bollinger Bands →

🔴
Current diagnosis · 2026-07-27
Downtrend zone

Current price $5.01 below the midline ($5.05). Normal downward flow. Below the Ichimoku cloud (bearish).

MACD (12 · 26 · 9) Expand ▼

An indicator that uses the difference between the short-term EMA (12) and long-term EMA (26) to identify trend reversals. When MACD rises above the Signal line, it is a buy signal (golden cross); when it falls below, it is a sell signal (death cross). About MACD →

🟡
Current diagnosis · 2026-07-27
Neutral zone — weak trend

MACD -0.412 · Signal -0.532 · Hist 0.120. Weak directional bias.

RSI(14) · Stochastics %K(14) Expand ▼

RSI measures short-term buying and selling pressure on a scale of 0–100. 30 or below = oversold (a rebound may be possible); 70 or above = overbought (a pullback may be possible). Stoch %K similarly measures short-term momentum strength. RSI · Learn more about Stochastics →

🔴
Current diagnosis · 2026-07-27
Bearish zone

RSI 44.7 (below the neutral level of 50). Selling pressure leads, indicating a weak trend. Stoch %K is also 35.1.

※ "Current diagnosis" is an automated interpretation based on standard thresholds and is for reference only. Make your own comprehensive judgment before trading.

Is it attractive at this price?

Cheaper than peers in its industry
Cheap on Vs. Assets·Vs. Sales
💡 How to read this — Compare against peers in the same industry to see what the price is cheap or expensive relative to. Example: cheap vs. earnings = stock price is low relative to what the company earns; expensive vs. assets = stock price is high relative to assets on the balance sheet.
🏢 Vs. Assets Cheap
🧾 Vs. Sales Cheap
🏢 Vs. Assets
PBR Price-to-Book Ratio
Price vs. the company's asset value — below 1 trades cheaper than assets
0.05x
✓ Very cheap
My positionTop 5%
Low range Average High range
Biotechnology 초소형주 median 1.35x · Top 1% — relatively cheap within the industry
💡 PBR 1 미만이면 청산가치 이하 (금융·제조업에서 특히 의미, IT는 낮은 비중)
🧾 Vs. Sales
PSR Price-to-Sales Ratio
Market cap vs. revenue — lower is cheaper relative to sales
3.34x
✓ Cheap
My positionMid-range
Low range Average High range
Biotechnology 초소형주 median 11.24x · Around the industry average
💡 PSR 2 이하 저평가, 10 초과면 고평가 (고성장 기업일 때만 정당화)
* Valuation is the stock's relative position within the industry peer group (same sector and market-cap range). Even when valuation looks attractive, check the 'Profitability' and 'Growth' sections too.
As of: Recent snapshot · Peer group: Biotechnology 초소형주

Who owns it?

Ownership flow shows some pressure
Insider modest net selling -4.2% · Institutional net selling -3.9% · Short interest light 1.8% · Short interest fell -3.0%p over the last 86 days
📈 Recent trading flow (6 months)
🧑‍💼 Insiders (executives & directors)
-4.2%
Insiders net selling
🏦 Institutions (funds & investors)
-3.9%
Institutions net selling
💡 Net change over the past 6 months. Shows how much insiders and institutions increased or reduced their holdings, in %.
👥 Holdings composition
🏦 Institutions 0.6%
Retail-led
Healthcare 초소형주 Median 14.2%
🧑‍💼 Insiders 1.9%
Typical level
Healthcare 초소형주 Median 16.1%
👤 Retail investors (estimated) 97.6%
Everyone excluding institutions and insiders
Institutions Insiders Retail (est.)
📉 Short-selling metrics
Short ratio
1.8%
Low — limited short-side pressure
Healthcare 초소형주 Median 3.9%
Past 86 days 📉 -3.0%p decrease
Short interest days to cover
0.0 days
Days needed to close short positions using average trading volume
🧮 Share count
Total shares outstanding 0.6M주
Float (tradable shares) 0.6M주
* Insider/institutional flows are based on net changes over the past 6 months. Trend is cumulative over the past 86 days.

How much does it pay in dividends?

This company does not pay a dividend

It may be a growth-focused firm reinvesting profits into expansion. Consider this growth-stock profile when investing.

Compare Industry Peers

💡 vs. sector average ▲ Favorable / ▼ Unfavorable (Lower PER and PBR are better; higher ROE and dividend yield are better)
Sorted by market cap, largest first
StockMarket CapPERPBRROEDividend YieldChange
SPRC SPRC This Stock
$2.9M- 0.1 -196.55% - -6.0%
LLY
$1.13T43.1 36.2 107.64% 0.58% +0.1%
JNJ
$640.9B30.8 7.5 25.74% 2.02% +1.0%
ABBV
$453.9B126.7 - 15221.82% 2.67% -0.9%
UNH
$379.3B26.9 3.9 12.49% 2.16% -0.7%
MRK
$323.0B36.8 7.0 18.97% 2.5% -0.2%
Sector Avg-26.12.7-48.83%1.23%-
📊
See the market at a glance with a real-time dashboard Track premarket, regular, and after-hours quotes, screeners, and heatmaps on a single screen

FAQ

What kind of company is 사이스파크(SPRC)?

사이스파크(SPRC) belongs to the Healthcare sector and operates in the Biotechnology industry.

What is the market cap of SPRC?

The market cap of SPRC is approximately $3M, ranking 5,774 within its sector.

What is the 52-week high and low for SPRC?

SPRC has recorded a 52-week high of $80.10 and a low of $2.98.

시황 · 실적발표 · 매수매도 신호, 가장 먼저 받아보세요 🔔 구독

면책조항: 본 콘텐츠는 참고 자료이며 투자 권유가 아닙니다. 모든 투자의 책임은 투자자 본인에게 있습니다.